Baseline patient characteristics
| Demographics | No (%) | Detail |
| Age, median (range), years | 63 (23–83) | |
| Gender | ||
| Male | 26 (47) | |
| Female | 29 (53) | |
| ECOG ≤1 | 53 (96) | |
| AJCC stage | ||
| III/M1a/M1b | 17 (31) | |
| M1c | 21 (38) | |
| M1d | 17 (31) | |
| LDH | ||
| Normal | 40 (73) | |
| Elevated | 15 (27) | |
| Mutation status | ||
| BRAF/NRAS wild type | 29 (53) | |
| BRAF | 17 (31) | |
| NRAS | 9 (16) | |
Autoimmune disorder (AD)* | ||
| Rheumatologic | 11 (20) | Rheumatoid arthritis—7, Sjogren’s syndrome—1, Behcet’s syndrome—1*, polymyalgia—1, uveitis—1* |
| Gastrointestinal | 14 (25) | Ulcerative colitis—7, Crohn’s disease—3, Celiac disease—4 |
| Endocrine | 21 (38) | Graves’ disease—8, Hashimoto’s thyroiditis—11*, type I diabetes—2* |
| Dermatologic | 7 (13) | Psoriasis—6, alopecia areata—1* |
| Neurologic | 2 (4) | Multiple sclerosis—2 |
| Hematologic | 1 (2) | ITP |
| Other | 2 (4) | Sarcoidosis—2 |
| Activity of AD | ||
| Clinically active | 10 (18) | |
| Not clinically active | 45 (82) | |
| Immunosuppression | 13 (24) | |
| Corticosteroids | 5 (9) | |
| SSA | 5 (9) | Sulfasalazine—1, mesalazine—2, plaquenil—1, methotrexate and plaquenil—1 |
| Corticosteroids+SSA | 3 (5) | Sulfasalazine, methotrexate, plaquenil |
| No immunosuppression | 42 (76) |
*Three of 55 patients had two concurrent autoimmune diseases.
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Group Performance Status; ITP, immune thrombocytopenic purpura; LDH, lactate dehydrogenase; SSA, steroid-sparing agent.